BMI Imaging Systems Showcases Advanced Digital Solutions at CLEARS 2025 Annual Training & Technology Seminar BMI Imaging joins California law enforcement professionals to discuss secure digitization, ...

Novo Nordisk’s oral semaglutide 25 mg achieved up to 16.6% weight loss in a landmark study, rivaling injectable Wegovy. The ...

Positive randomized 3-month REMAIN-1 Midpoint Cohort data showed single Revitaprocedure maintained weight loss after GLP-1 discontinuation; ...

Thermolysis has been recognized for its ability to turn rCF into a building material that enhance durability, extend lifespan and reduce maintenance needs.

Novo Nordisk reports Wegovy users lost 21% body weight and saw improved heart health markers, as EMA and FDA reviews near for ...

The MarketWatch News Department was not involved in the creation of this content.-- Post hoc analyses include data showing investigational oral semaglutide 25 mg use was associate ...

Regular orange juice consumption reprograms immune-cell gene activity linked to blood pressure, lipid metabolism, and ...

Medicare will cover GLP-1 weight loss drugs for specific patient groups, beginning in mid-2026, under a deal struck with drugmakers.

The US Food and Drug Administration (FDA) has extended the review period for expanded approval of Rhythm Pharmaceuticals’ ...

OIF convened its Q4 2025 Technical and MA&E Committees Meeting in Busan, South Korea, Nov. 3?7, where global members gathered to advance the organization's work across optical, electrical, management ...

Mean weight loss of 19.2%I at 6 mg with no plateau and favorable safety profile in 48-week Phase 3 clinical trial –– Data builds on previously ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.